Trial Profile
Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs LY 2599666 (Primary) ; Solanezumab
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 20 Jul 2017 Results (n=43) presented at the Alzheimer's Association International Conference 2017
- 06 Jan 2017 Status changed from active, no longer recruiting to discontinued.
- 05 Jan 2017 Status changed from recruiting to active, no longer recruiting.